Bioject to Report Third Quarter 2009 Financial Results

• Press Release
• Source: Bioject Medical Technologies Inc.
• On 4:30 pm EDT, Friday October 30, 2009

PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc., (OTCBB:BJCT - News), a leading developer of needle-free injection therapy systems, announced today that the Company will report its financial results for the third quarter ended September 30, 2009 on Wednesday, November 4, 2009, after the close of the financial markets. Management will conduct a conference call on Thursday, November 5, 2009 at 10:00 a.m. Eastern Time to review the results for the quarter. Ralph Makar, President and CEO, Dr. Rick Stout, Executive Vice President and Chief Medical Officer and Chris Farrell, Vice President of Finance, will be hosting the call.

Related Quotes

Symbol	Price	Change
BJCT.OB	0.09	+0.02

{"s" : "bjct.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Live audio of the conference call will be available to investors, members of the news media and the general public. To participate in the call via telephone, please dial 1-877-407-8037. A conference call replay will also be available until November 12, 2009. To listen to the replay, please dial 1-877-660-6853, replay account number 7303, identification number 336717.

Bioject Medical Technologies Inc., based in Portland, Oregon, is an innovative developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS provide an empowering technology and work by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The Company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.

For more information about Bioject, visit www.bioject.com.

Bioject Medical Technologies Inc.
Ralph Makar, President and CEO, 503-692-8001 ext. 4137
or
Chris Farrell, Vice President of Finance, 503-692-8001 ext. 4132